TABLE 1.

Summary of case series of patients with bloodstream infections or bone and joint infections treated with oritavancin^a

Reference	n	Infection(s)	Bacterium or bacteria (n)	Most frequent dosage(s)	Duration/no. of doses	Success, n (%)b	Adverse event(s) (n)
Bloodstream infections
Bhavnani et al., 2006 (73)	55	Bacteremia	S. aureus (55)	5–10 mg/kg/day	10–14 days	45 (78)	N/R
Johnson et al., 2015 (109)	1	PVE	VR E. faecium (1)	1,200 mg every 48 h × 3 doses, then 1,200 mg weekly × 6 wk, then 1,200 mg biweekly × 10 wk	14 doses	1 (100)c	Anorexia, nausea, elevated LFTs (1)
Stewart et al., 2017 (82)	6	Bacteremiad	MSSA (4), CoNS (1), Enterococcus spp. (1)	1,200 mg	1 dose	4 (66.7)	None
Stewart et al., 2017 (82)	1	NVE	S. agalactiae (1)	1,200 mg	1 dose	0 (0)	None
Datta et al., 2018 (74)	3	Bacteremia	MRSA (1), S. gallolyticus (1), Granulicatella adiacens (1)	1,200 mg	1 dose	3 (100)	N/R
Brownell et al., 2020 (76)	4	Endocarditis	Not specifiede	1,200 mg then 800–1,200 mg weekly	N/Re	4 (100)	None
Redell et al., 2019 (77)	7	Bacteremia	MRSA (2), MSSA (1), S. epidermidis (2), other (2)	1,200 mg once	1 dose	7 (100)	Not specified (29)f
Schulz et al., 2018 (80)	1	Bacteremia	VR E. faecium (1)	1,200 mg then 800 mg weekly	4 doses	0 (0)	None
Total	78					64 (82)
Bone and joint infections
Van Hise et al., 2020 (75)	134	Acute osteomyelitis	MSSA (35), MRSA (108), VISA (2), VRE (7)	1,200 mg once then 800 mg weekly	4–5 doses	118 (88.1)	Hypoglycemia (3), tachycardia (2)
Brownell et al., 2020 (76)	16	Osteomyelitis, diabetic foot, IAI	Not specifiedg	1,200 mg then 800–1,200 mg weekly	N/Rg	16 (100)	Not specified (3)f
Redell et al., 2019 (77)	25	Acute osteomyelitis, septic arthritis, IAI	Not specifiedg	1,200 mg once or 1,200 mg every 6–14 days	1–10 doses	19 (76)	Not specified (29)f
Chastain and Davis, 2019 (78)	9	Chronic osteomyelitis	MRSA (5), other (4)i	1,200 mg LD then 1,200 mg every 13–52 days	2–6 doses	9 (100)	None
Dahesh et al., 2019 (66)	1	IAI	VR E. faecium (1)	1,200 mg weekly × 2 wk then 800 mg weekly	10 doses	1 (100)	N/R
Ruggero et al., 2018 (79)	1	Acute osteomyelitis	MRSA (1)	1,200 mg every 2–4 wk	5 doses	1 (100)	N/R
Schulz et al., 2018 (80)	4	Acute and chronic osteomyelitis, septic arthritis, diskitis	MSSA (1), other (3)i	1,200 mg then 800 mg weekly	2–8 doses	2 (50)h	Anemia and leukopenia (1)
Foster et al., 2017 (110)	1	IAI	Daptomycin-nonsusceptible VR E. faecium (1)	1,200 mg weekly	6 doses	1 (100)	None
Delaportas et al., 2017 (81)	1	Acute osteomyelitis	MSSA (1)	1,200 mg weekly	7 doses	1 (100)	None
Stewart et al., 2017 (82)	1	Bursitis	MRSA (1)	1,200 mg once	1 dose	1 (100)	Hearing loss (1)
Total	193					169 (87.6)

^aVRE, vancomycin-resistant Enterococcus; CoNS, coagulase-negative staphylococci; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; N/R, not reported; VISA, vancomycin-intermediate S. aureus; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; IAI, implant-associated infection; LD, loading dose.

^bDefinitions of clinical success were heterogeneous across the studies. For details, refer to the individual publication.

^cClinical improvement—partial resolution of clinical signs and symptoms.

^dIncludes bacteremia with wound infection, bacteremia with abscesses with and without osteomyelitis, and bacteremia with endocarditis.

^eNot reported for infective endocarditis.

^fCorresponds to the total cohort in studies that included cases with different sources of infection.

^gNot specified for bone and joint infections.

^hCure, 2 (50%); improvement, 2 (50%).

ⁱIncludes sterile cultures or unavailable cultures.